MARKET

VSTM

VSTM

Verastem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.220
0.000
0.00%
After Hours: 1.210 -0.01 -0.82% 19:40 10/26 EDT
OPEN
1.220
PREV CLOSE
1.220
HIGH
1.240
LOW
1.160
VOLUME
1.64M
TURNOVER
--
52 WEEK HIGH
4.670
52 WEEK LOW
0.8300
MARKET CAP
206.83M
P/E (TTM)
-0.8688
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Hedge Funds Are Getting More Bullish On Verastem Inc (VSTM)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the second quarter. You can find articles about an individual hedge fund’s trades on numerous financial […]
Insider Monkey · 10/14 14:26
Verastem (VSTM) Jumps: Stock Rises 7.1%
Verastem (VSTM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Zacks · 10/08 13:38
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the grant of options to purchase 39,000 shares of its common stock to three new employees and the grant of 22,500 restricted stock
Business Wire · 10/06 12:00
Verastem Oncology Announces Closing Of COPIKTRA Sale To Secura Bio
Verastem Now Focused on Development of VS-6766 and Defactinib Combination in Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer Registration-Directed Clinical Trials in LGSOC and KRAS Mutant
Benzinga · 09/30 12:57
Verastem Oncology Announces Closing of COPIKTRA® (duvelisib) Sale to Secura Bio
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that it has completed the sale of Verastem's COPIKTRA (duvelisib), a marketed oral inhibitor of phosphoinositide 3-kinase
Business Wire · 09/30 12:54
How Many Verastem, Inc. (NASDAQ:VSTM) Shares Do Institutions Own?
Every investor in Verastem, Inc. (NASDAQ:VSTM) should be aware of the most powerful shareholder groups. Large...
Simply Wall St. · 09/18 16:50
Arrowhead Pharmaceuticals, Myomo leads healthcare gainers, Novus Therapeutics, Jounce Therapeutics among major losers
Gainers: Arrowhead Pharmaceuticals (ARWR) +46%, Myomo (MYO) +38%, AxoGen (AXGN) +15%, Covetrus (CVET) +14%, Inovio Pharmaceuticals (INO) +13%.Losers: Novus Therapeutics (NVUS) -13%, Jounce Therapeutics (JNCE) -10%, Syneos Health (SYNH) -7%, Verastem (VSTM) -5%, Evogene (EVGN) -5%.
Seekingalpha · 09/16 15:00
Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced updated results from the ongoing investigator-initiated Phase 1/2 FRAME study evaluating VS-6766, its RAF/MEK inhibitor, in combination
Business Wire · 09/16 11:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VSTM. Analyze the recent business situations of Verastem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VSTM stock price target is 3.833 with a high estimate of 5.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 190
Institutional Holdings: 75.54M
% Owned: 44.56%
Shares Outstanding: 169.53M
TypeInstitutionsShares
Increased
30
24.21M
New
83
-12.16M
Decreased
24
25.79M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.79%
Pharmaceuticals & Medical Research
-1.00%
Key Executives
President/Chief Operating Officer
Daniel Paterson
Chief Executive Officer/Director
Brian Stuglik
Chief Financial Officer
Robert Gagnon
Lead Director/Independent Director
Michael Kauffman
Independent Director
Timothy Barberich
Independent Director
Gina Consylman
Independent Director
Alison Lawton
Independent Director
Eric Rowinsky
Independent Director
Bruce Wendel
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VSTM
Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a potential combination therapy for various solid tumors. It is engaged in running clinical trials in cancers where there are limited treatment options, including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer. VS-6766 is an inhibitor of the RAF/MEK signaling pathway. VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Verastem Inc stock information, including NASDAQ:VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VSTM stock methods without spending real money on the virtual paper trading platform.